Medical/Pharmaceuticals News & Press Release Distribution

Medical/Pharmaceuticals

APAC
Global

OcuMension (01477.HK) Invests Over RMB 123.8 Million in Research, Technology and Self-development Progress in Tandem, Main Product Sales Show Comprehensive Growth

SHANGHAI, March 21, 2024 /PRNewswire/ -- On the evening of March 21st, OcuMension Therapeutics (Shanghai) Co., Ltd. (01477.HK, hereinafter referred to as "OcuMension" or the "Company") disclosed its 2023 annual performance report. The company achieved a total operating income ofRMB 246.4 million ...

2024-03-21 22:44 3288

100% CBR! FDA Granted ODD to Biostar Pharma's Utidelone Capsule (UTD2) for the Treatment of Gastric Cancer

SAN FRANCISCO, March 21, 2024 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the development and commercialization of innovative oncology drugs, announced today that their ...

2024-03-21 20:30 1187

FDA Grants Orphan Drug Designation to Cevidoplenib for ITP

PANGYO, South Korea, March 21, 2024 /PRNewswire/ -- Oscotec Inc. has secured orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA) for its SYK inhibitor, Cevidoplenib, to treat immune thrombocytopenia (ITP). Oscotec has successfully completed phase 2 study in patients wit...

2024-03-21 20:00 1310

Henlius 2023 Annual Results: Revenue surpassed RMB5.39 billion with a net profit RMB546 million, first full-year profitability achieved

SHANGHAI, March 21, 2024 /PRNewswire/ -- Henlius (2696.HK) announced its 2023 annual results. During the reporting period, Henlius' revenue reached about RMB5.3949 billion, representing an increase of 67.8% YoY, and recorded a net profit ofRMB546.0 million. This is the first time for Henlius to a...

2024-03-21 19:47 3009

Biosion to Present Three Posters at the 2024 AACR Meeting

NEWARK, Del. and NANJING, China, March 21, 2024 /PRNewswire/ -- Biosion, a global, clinical-stage biotechnology company, today announced upcoming presentations of pre-clinical data for its oncology pipeline assets, including BSI-111, an anti-CD16a monoclonal antibody, BSI-730, a HER2/PD-L1 bispec...

2024-03-21 19:00 1118

HanAll Biopharma Reports Full-Year 2023 Financial Results and Provides Business Update

* Full-year 2023 net revenue reaches 135 billion KRW, driven by strong sales growth. * R&D momentum persisted with promising developments in anti-FcRn antibodies HL161ANS and batoclimab, positioning them as potentially best-in-class treatments for lgG-mediated autoimmune diseases. * Anticip...

2024-03-21 19:00 1146

111, Inc. Announces Fourth Quarter and Fiscal Year 2023 Financial Results

SHANGHAI, March 21, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services inChina, today announced its unaudited financial results for the fourth qua...

2024-03-21 16:47 2362

Mabwell Presented IDDC™ Platform Technology and ADC Drug Development Achievements at the 14th World ADC London

SHANGHAI, March 21, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, published "Mtoxin™ Payload Applied in IDDC™ ADC Platform Significant Increases Therapeutic Index and Overcome MultiDrug Resistance in Various Tumor" as poster ...

2024-03-21 14:11 1181

Mabwell Presented IDDC™ Platform Technology and ADC Drug Development Achievements at the 14th World ADC London

SK bioscience Exports Influenza Vaccine to Thailand, Entering Southern Hemisphere Market

* Company exported 440,000 doses to Thailand, marking its entry into the Southeast Asian market and the Southern Hemisphere market. * Company has obtained marketing authorizations in 12 countries, with additional approvals underway in 10 countries to expand its market worldwide. BANGKOK and S...

2024-03-21 13:24 1566

SK bioscience Exports Influenza Vaccine to Thailand, Entering Southern Hemisphere Market

SINGAPORE'S "HUSTLE CULTURE" TAKES ITS TOLL: THE AIR STATION AND RESMED LAUNCH INITIATIVE TO ADDRESS WORK-INDUCED SLEEP ISSUES

* Global survey reveals that 39% of Singaporeans grapple with sleep, impacting health and productivity. * The Air Station and ResMed's upcoming joint initiative, "Discover Your Sleep Superpowers," aims to empower Singaporeans with free sleep screenings, complimentary sleep consultations with ...

2024-03-21 09:35 1502

TreeFrog's Chief Scientific Officer & Co-founder, Maxime Feyeux, to present at The 23rd Congress of the Japanese Society for Regenerative Medicine (JSRM)

- TreeFrog Therapeutics demonstrates fast, sustained, full motor recovery in preclinical models for Parkinson's Disease cell therapy program using C-Stem™ proprietary technology[1] - BORDEAUX, France, March 21, 2024 /PRNewswire/ -- TreeFrog Therapeutics, a cell therapy development company with...

2024-03-21 07:30 1487

Jiangsu Recbio Technology Co., Ltd. announced 2023 annual results report and latest progress

TAIZHOU, China, March 21, 2024 /PRNewswire/ -- Innovative vaccine company Recbio (02179.HK) announced its latest progress and annual results for 2023. The company always adhered to the mission of " Protect Human Health With Best-In-Class Vaccines", and achieved the following milestones and progre...

2024-03-21 00:22 2857

Antengene Initiates Phase II Dose Expansion Study of Claudin 18.2 ADC ATG-022 in China and Australia

SHANGHAI and HONG KONG, March 20, 2024 /PRNewswire/ -- Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class therapeutics in he...

2024-03-20 20:30 2097

Antennova Completes First Dosing Cohort for Anti-CD24 mAb, ATN-031, in the Phase I PERFORM Study

* ATN-031 (also known as ATG-031), is the first anti-CD24 antibody to advance to the clinic in oncology inthe United States * The Phase I PERFORM trial, ongoing at four major U.S. cancer centers, is evaluating the safety and preliminary efficacy of ATN-031 in patients with advanced solid tumor...

2024-03-20 20:30 2161

Innovent Announces 2023 Annual Results and Business Updates

A transformative year of strong performance and material innovation progress ROCKVILLE, M.D. and SUZHOU, China, March 20, 2024 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality med...

2024-03-20 19:44 3189

Johnson Matthey signs agreement to sell its Medical Device Components business for US$700m

Johnson Matthey Plc This announcement contains inside information LONDON, March 20, 2024 /PRNewswire/ -- Johnson Matthey Plc (JM) announces that it has signed a definitive agreement to sell 100% of its Medical Device Components business (MDC) to Montagu Private Equity (Montagu) for cash consider...

2024-03-20 19:10 2042

STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses

LAKE FOREST, Calif., March 20, 2024 /PRNewswire/ -- STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, today announced that more than three million ICLs have bee...

2024-03-20 16:22 1711

STAAR Surgical Celebrates Three Million Implantable Collamer® Lenses

BGI Group Celebrates 20th Anniversary of Partnerships in Healthcare and Genomics in Thailand

BANGKOK, March 20, 2024 /PRNewswire/ -- This year marks the twentieth anniversary of BGI Group's close relationship with the Kingdom ofThailand. Initially both parties were brought together through an international humanitarian rescue effort during the Indian Ocean tsunami where BGI worked with ...

2024-03-20 12:39 1725

Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies

Proceeds to Support Advancement of Engrail's Pipeline for Neuropsychiatric and Neurodevelopmental Disorders SAN DIEGO, March 20, 2024 /PRNewswire/ -- Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the development of transformational therapies to impro...

2024-03-20 11:00 1517

Docquity enables Italian biopharmaceutical company Menarini to double HCP reach and engagement in Malaysia

* A Docquity client since 2021, Menarini Malaysia further engaged the platform to raise awareness among target HCPs on multimodal approaches to post-surgery pain management and recovery * Docquity's Awareness to Advocacy (A2A) Program, backed by its in-depth HCP network insights, droveMenarini...

2024-03-20 10:00 1485

1 ... 10 11 121314 15 16 ... 576